A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™)

A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™)

This is a single-center prospective, open-label, single arm interventional study to test the safety and efficacy of recently described ChipEXO™ for severe COVID-19 pneumonia. The ChipEXO™ is a natural product derived from convalescent human immune plasma of patients recovered from moderate COVID-19...

Full description

Bibliographic Details
Main Authors: Fethi Gül, Zeynep Burcin Gonen, Olcay Y. Jones, Neslihan Pakize Taşlı, Gökmen Zararsız, Ekrem Ünal, Aykut Özdarendeli, Fikrettin Şahin, Ahmet Eken, Semih Yılmaz, Musa Karakukçu, Oğuz Kaan Kırbaş, Nur Seda Gökdemir, Batuhan Turhan Bozkurt, Yusuf Özkul, Burçin Doruk Oktay, Muhammet Ali Uygut, Ismail Cinel, Mustafa Çetin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
COVID-19
Coronavirus disease
Severe acute respiratory syndrome-coronavirus-2
SARS-CoV-2
exosomes
convalescent plasma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.963309/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.963309/full

Similar Items